Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150357 | 0.84 | MAPT (0.44) | PIK3CAKCNQ2 | |
| SCHEMBL21090110 | 0.84 | PIK3CA (0.58) | PIK3CAALDH1A1HDAC1DAO | |
| SCHEMBL6864288 | 0.83 | CES2 (0.46) | MAPK8SIGMAR1CES2CES1MAOA | |
| SCHEMBL4108950 | 0.82 | KMT2A (0.44) | KCNQ2HTTALDH1A1HDAC1DAO | |
| SCHEMBL4691645 | 0.82 | CYP1A2 (0.42) | MAOAMAOBPIK3CAALDH1A1HDAC1 | |
| SCHEMBL12672485 | 0.82 | MMP13 (0.47) | PIK3CAALDH1A1HDAC1HDAC8DAO | |
| SCHEMBL154429 | 0.81 | KDM4E (0.55) | MAPK8CES2CES1MAOAMAOB | |
| SCHEMBL28501277 | 0.80 | MAPK8 (0.42) | MAPK8SIGMAR1CES2CES1MAOA | |
| SCHEMBL1874608 | 0.80 | DAO (0.42) | MAPK8CES2CES1MAOAMAOB | |
| SCHEMBL5200711 | 0.80 | KIF11 (0.50) | KCNQ2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3206057-A | — | — | None | — | — | JP | disclosed |
| JP-3206055-A | — | — | None | — | — | JP | disclosed |
| CN-119823019-A | Indole compound with effect of treating idiopathic pulmonary fibrosis as well as preparation method and application thereof | 沈阳药科大学 | 2025-04-15 | — | — | CN | disclosed |
| US-20240316043-A1 | BROMODOMAIN INHIBITORS FOR CANCER THERAPY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024178304-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-116715634-A | Compound, pharmaceutical composition and application thereof in preparation of vasodilation drugs | 山东第一医科大学(山东省医学科学院) | 2023-09-08 | — | — | CN | disclosed |
| WO-2018184976-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND USE OF SAME | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | WO | disclosed |
| EP-2346865-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2015-07-15 | — | — | EP | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8299075-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| WO-2002016343-A1 | TETRAHYDROPYRAN DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016344-A1 | TETRAHYDROPYRAN DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1140906-A1 | IMIDAZOLONES AND THEIR USE IN TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035907-A1 | IMIDAZOLONES AND THEIR USE IN TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| US-6046331-A | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| JP-H03206057-A | LIQUID CRYSTALLINE COMPOUND OF TOLANE-TYPE | CHISSO CORP | 1991-09-09 | — | — | JP | disclosed |
| JP-H03206055-A | LIQUID CRYSTALLINE COMPOUND AND LIQUID CRYSTALLINE COMPOSITION | SEIKO EPSON CORP | 1991-09-09 | — | — | JP | disclosed |
| US-4839091-A | SUPERIOR COMPATIBILITY AT LOW TEMPERATURES; LARGE OPTICAL ANISOTROPY | CHISSO CORPORATION (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0295602-A1 | Tolan derivative and liquid crystal composition containing the same | Chisso Corporation (JP) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316043-A1 | BROMODOMAIN INHIBITORS FOR CANCER THERAPY | BRDT, BRD4, BRD3 | MAPK8 1265/4885SIGMAR1 3427/4885CES2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.